Page 14 - CUA 2020_Endourology

2020 CUA Abstracts

UP-1.18. Table 2. Pathological outcomes
1st quintile (0– 2nd quintile (20– 3rd quintile (40– 4th quintile (60–- 5th quintile (80– p
20th percentile, 40th percentile, 60th percentile, 80th percentile, 100th percentile,
n=519) n=537) n=533) n=538) n=527)
n % n % n % n % n %
Pathology Primary 0.5056
Gleason score grade
≤6 3 97 18.69% 114 21.31% 125 23.50% 123 22.86% 116 22.10%
7 3 284 54.72% 299 55.89% 294 55.26% 303 56.32% 289 55.05%
4 98 18.88% 89 16.64% 88 16.54% 76 14.13% 89 16.95%
≥8 3/4/5 40 7.71% 33 6.17% 25 4.70% 36 6.69% 31 5.90%
Upgrade in Gleason score 0.0256
No 411 79.19% 428 79.70% 415 77.86% 393 73.05% 390 74.0%
Yes 108 20.81% 109 20.30% 118 22.14% 145 26.95% 137 26.0%
Increase in score ≥2 4 0.77% 5 0.93% 3 0.56% 9 1.67% 6 1.14% 0.4310
Pathology T T stage 0.4009
stage ≥3a
Yes pT3a 168 32.37% 154 28.68% 137 25.70% 149 27.70% 140 26.57%
pT3b 39 7.51% 45 8.38% 44 8.26% 51 9.48% 47 8.92%
pT4 0 0.00% 1 0.19% 2 0.38% 0 0.0% 0 0.0%
No pT2 312 60.1% 337 62.76% 350 65.67% 338 62.83% 340 64.52%
Pathology N stage 0.0781
pNX 281 54.14% 315 58.66% 295 55.66% 313 58.18% 327 62.29%
pN0 229 44.12% 206 38.36% 223 42.08% 214 39.78% 181 34.48%
pN1 9 1.73% 16 2.98% 12 2.26% 11 2.04% 17 3.24%
Upstage 0.4806
No 331 63.78% 357 66.48% 367 68.86% 359 66.73% 358 67.93%
Yes 188 36.22% 180 33.52% 166 31.14% 179 33.27% 169 32.07%
Surgical margins 0.0110
Positive 128 24.66% 101 18.81% 100 18.76% 110 20.45% 85 16.13%
Negative 391 75.34% 436 81.19% 433 81.24% 428 79.55% 442 83.87%

UP-1.20
Predicting adverse pathological outcomes and biochemical
UP-1.18. Table 3. Multivariate analysis of positive surgical recurrence in pre-prostatectomy patients using different
margin involvement and upgrade quantification methods of percentage Gleason grade 4/5 disease
Upgrade on prostate biopsy
1
2,3
4
1
Effect Odds ratio (95% CI) Jethro C.C. Kwong , Simona Minotti , Adrian Cozma , Ashkan Javidan ,
5
Amna Ali , Munir A. Jamal , Thomas Short , Frank F. Papanikolaou , John
5
2
5
Pre-treatment serum total testosterone 1.273 (0.954–1.698) R. Srigley , Andrew H. Feifer 2,5
6
(log-transformed) 1 Faculty of Medicine, University of Toronto, Toronto, ON, Canada; Institute
2
Age 1.029 (1.013–1.046) for Better Health, Trillium Health Partners, Mississauga, ON,
Canada; Department of Statistics and Quantitative Methods, University
3
Baseline PSA 1.051 (1.035–1.068)
4
of Milano-Bicocca, Milano, Italy; Department of Radiation Oncology,
Clinical T stage 1.212 (1.001–1.468) University of Toronto, Toronto, ON, Canada; Department of Surgery,
5
6
First positive biopsy Gleason score 0.051 (0.039–0.066) University of Toronto, Toronto, ON, Canada; Department of Laboratory
Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
Surgical margins
Introduction: Emerging evidence suggests that percentage Gleason grade
Effect Odds ratio (95% CI) 4/5 disease (% 4/5) adds prognostic value to predicting adverse pathologi-
Pre-treatment serum total testosterone 0.628 (0.491–0.804) cal outcomes and biochemical recurrence (BCR) in pre-prostatectomy
(log-transformed) patients. We compared three quantification methods of % 4/5 with con-
Age 1.004 (0.990–1.018) ventional Gleason parameters in predicting these outcomes.
Methods: Patients who underwent an open retropubic radical prostatec-
Baseline PSA 1.057 (1.042–1.072) tomy from 2002–2016 were included. Adverse pathological outcomes
Clinical T stage 1.315 (1.149–1.504) included extra-prostatic extension (EPE), regional lymph node involve-
First positive biopsy Gleason score 1.106 (0.959–1.277) ment (RLNI), seminal vesicle invasion (SVI), lymphovascular invasion
(LVI), and positive margins (PSM). BCR was defined as prostate-specific
antigen (PSA) >0.2 ng/mL. We used multivariate logistic regression to
S52 CUAJ • June 2020 • Volume 14, Issue 6(Suppl2)